The kratom industry is facing continued scrutiny as a contract manufacturer recently received a warning letter from the US FDA, coincidentally made public on the same day the published standards for safety from the American Kratom Association were released.
While the FDA warning letter to Avalon Packaging, Inc., a contract manufacturer of kratom, cited issues with manufacturing, including salmonella contamination, the agency refrained referencing its 2017 findings that found kratom constituent ingredients to be opioids and potentially in need of being scheduled as controlled substances by the DEA.
While the FDA warning letter to Avalon Packaging, Inc., a contract manufacturer of kratom, cited issues with manufacturing, including salmonella contamination, the agency refrained referencing its 2017 findings that found kratom constituent ingredients to be opioids and potentially in need of being scheduled as controlled substances by the DEA.
